Stocktoria
Minerva Neurosciences, Inc. NERV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-25
Chart by TradingView
2/9
Piotroski F — financial health
-19.18
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | $0 | $0 | $0 | $0 |
| Operating income | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.4M |
| Net income | -$293.4M | $1.4M | -$30.0M | -$32.1M | -$49.9M |
| Operating cash flow | -$13.5M | -$19.6M | -$14.8M | -$24.6M | -$24.6M |
| Free cash flow | — | — | — | -$24.7M | — |
| Total assets | $98.0M | $37.1M | $56.9M | $55.1M | $77.1M |
| Total liabilities | $233.8M | $62.8M | $85.4M | $75.1M | $69.1M |
| Shareholders' equity | -$140.7M | -$25.7M | -$28.5M | -$20.0M | $8.0M |
| Ratios | |||||
| Return on assets | -299.5% | 3.9% | -52.7% | -58.3% | -64.7% |
| Return on equity | 208.5% | -5.6% | 105.4% | 160.3% | -625.7% |
| Current ratio | 36.28 | 7.85 | 12.57 | 29.15 | 22.07 |
| Revenue growth | — | — | — | — | -100.0% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 89,700 | $540,444 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.18 (distress)
- Working capital / assets 0.825
- Retained earnings / assets -7.031
- EBIT / assets -0.154
- Equity / liabilities -0.602
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001598646 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.